Efgartigimod in Sjögren’s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)
Annals of the Rheumatic Diseases · 2026-07 · 85 (7) · 1341-1350
DOI: 10.1016/j.ard.2026.03.019 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-07. Verfasst von Isabelle Peene und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; VIB Center for Inflammation Research, Ghent University, Ghent, Belgium. Electr…. Hauptthemen laut MEDLINE: Sjogren's Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis, argenx nv, Micropalaeontological Society.
Abstract (Originalsprache)
OBJECTIVES: This study aimed to evaluate the efficacy and safety of intravenous (IV) efgartigimod in adults with Sjögren's disease (SjD). METHODS: We conducted a randomised, double-blinded, placebo-controlled, phase 2, proof-of-concept multicentre study (hereafter referred to as RHO). Participants were randomised 2:1 to receive efgartigimod IV 10 mg/kg or placebo once weekly for 24 weeks. The primary outcome was the proportion of Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) responders on ≥3 of 5 items (systemic disease activity, patient-reported symptoms, tear and salivary gland function, and serology) at week 24. Secondary outcomes included the proportion with candidate Sjögren's Tool for Assessing Response (cSTAR) score ≥5 at week 24 and safety. No formal statistical hypothesis was tested. RESULTS: Thirty-four participants were randomised to efgartigimod (N = 23) or placebo (N = 11); 31 were included in the efficacy analysis. A numerically higher proportion of efgartigimod-treated participants responded to ≥3 items of CRESS at week 24 compared with placebo (45.5% vs 11.1%; treatment difference 34.4%). More specifically, efgartigimod scored higher on 4 of 5 CRESS items. Similarly, a numerically higher proportion of efgartigimod-treated participants scored ≥5 on the cSTAR at week 24 (efgartigimod, 54.5% vs placebo, 33.3%). Treatment-emergent adverse events were reported in 87.0% of efgartigimod-treated participants compared with 63.6% of those on placebo; all were grade 1 or 2 in severity. CONCLUSIONS: Data from the RHO study support proof of concept for efgartigimod in SjD. Further evaluation in a phase 3 study of efgartigimod in individuals with SjD is warranted. The trial was registered with ClinicalTrials.gov (NCT05817669).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; VIB Center for Inflammation Research, Ghent University, Ghent, Belgium. Electronic address: isabelle.peene@ugent.be.
- Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; VIB Center for Inflammation Research, Ghent University, Ghent, Belgium.
- Clinical Science, argenx BV, Zwijnaarde, Belgium.
- Clinical, IQVIA, Durham, NC, USA.
Förderung
- Novartis
- argenx nv
- Micropalaeontological Society
Zitieren
APA
Peene, I., Verstappen, G. M., Arends, S., Kroese, F. G. M., De Boeck, K., Achten, H., Papadopoulou, D., Jacobs, J., Bowen, E., Teperov, E., Meyvisch, P., Fardipour, P., Kelly, A., Brahmbhatt, J., Elewaut, D., & Bootsma, H. (2026). Efgartigimod in Sjögren’s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO). Annals of the Rheumatic Diseases, 85(7), 1341-1350. https://doi.org/10.1016/j.ard.2026.03.019
Vancouver
Peene I, Verstappen GM, Arends S, Kroese FGM, De Boeck K, Achten H, et al. Efgartigimod in Sjögren’s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO). Annals of the Rheumatic Diseases. 2026;85(7):1341-1350. doi:10.1016/j.ard.2026.03.019
BibTeX
@article{Peene2026,
author = {Peene, Isabelle and Verstappen, Gwenny M and Arends, Suzanne and Kroese, Frans G M and De Boeck, Kristel and Achten, Helena and Papadopoulou, Despoina and Jacobs, Julie and Bowen, Edward and Teperov, Elizabeth and Meyvisch, Paul and Fardipour, Parvin and Kelly, Andrew and Brahmbhatt, Janki and Elewaut, Dirk and Bootsma, Hendrika},
title = {Efgartigimod in Sjögren’s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {7},
pages = {1341--1350},
doi = {10.1016/j.ard.2026.03.019}
}
EUVIMED